InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, will report financial results for the three months ended September 30, 2019, which is the Company’s first quarter of fiscal year 2020 (“1Q20"), on Friday, November 8, 2019.
VANCOUVER, Nov. 4, 2019 /PRNewswire/ -InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing technology for the production of pharmaceutical-grade cannabinoids as well as a pipeline of medications targeting diseases with high unmet medical needs, will report financial results for the three months ended September 30, 2019, which is the Company's first quarter of fiscal year 2020 ("1Q20"), on Friday, November 8, 2019. Conference Call & Webcast:
Replays, Available through November 15, 2019:
The Company's full financial statements and related MD&A for the three months ended September 30, 2019 will be available at www.sedar.com on November 8, 2019. About InMed: Cautionary Note Regarding Forward-Looking Information: All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law. NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
SOURCE InMed Pharmaceuticals Inc. |
||||||||||||||||||||
Company Codes: OTC-QX:IMLFF, Toronto:IN |